E.U. Agency in Limbo as Hidden Costs of ‘Brexit’ Continue to Mount
http://www.nytimes.com/2016/12/25/wo...exit.html?_r=0
My bolding
This would be on top of the price rises already in the pipeline thanks to the collapse in the pound - still at least we have the £350m a week that was promised - oh hang on.
http://www.nytimes.com/2016/12/25/wo...exit.html?_r=0
My bolding
Quote:
“When it switched offices in London not long ago, the European Medicines Agency signed a 25-year lease on a shiny new building in the east of the city.
Just two years later, the organization is preparing to relocate again, but this time its likely move has sent tremors through Britain’s pharmaceutical industry and raised fears over public safety.”
“When it switched offices in London not long ago, the European Medicines Agency signed a 25-year lease on a shiny new building in the east of the city.
Just two years later, the organization is preparing to relocate again, but this time its likely move has sent tremors through Britain’s pharmaceutical industry and raised fears over public safety.”
Quote:
“That surprise decision means the organization, a European Union agency, will almost certainly have to leave Britain, just one of the many unanticipated consequences of the vote that is forcing the country to unscramble 40 years of European integration.
From the car industry to finance, that task is proving messier and more complicated than expected, with effects more far-reaching than anyone imagined — in this case with worrying implications for Britain’s vibrant and successful biotech and pharmaceuticals sector and Europe’s public health.
With the agency’s days in London almost certainly numbered, cities like Stockholm and Strasbourg, France,are scrambling to lure its team of experts, who license drugs and monitor their use for safety. But the uncertainty has left the agency’s executive director, Guido Rasi, “very worried” as experts start to quit and others are recruited away.”
“That surprise decision means the organization, a European Union agency, will almost certainly have to leave Britain, just one of the many unanticipated consequences of the vote that is forcing the country to unscramble 40 years of European integration.
From the car industry to finance, that task is proving messier and more complicated than expected, with effects more far-reaching than anyone imagined — in this case with worrying implications for Britain’s vibrant and successful biotech and pharmaceuticals sector and Europe’s public health.
With the agency’s days in London almost certainly numbered, cities like Stockholm and Strasbourg, France,are scrambling to lure its team of experts, who license drugs and monitor their use for safety. But the uncertainty has left the agency’s executive director, Guido Rasi, “very worried” as experts start to quit and others are recruited away.”
Quote:
“Some hope that the disruption can be avoided, and that the agency might remain where it is, with Britain continuing to participate. That seems plausible only if Britain seeks a very close relationship with the European Union, as Norway, Iceland and Liechtenstein did. But those countries agreed to be integrated into the single market, accepting free movement of people as well as goods, capital and services. Prime Minister Theresa May argues that Britons voted against such open borders, and is likely to resist that move.
Outside the bloc, Britain might opt to duplicate the agency’s work, but at a significant cost. Drug companies might require two authorizations for new products — one British, one European — pushing up the prices of medicine.”
“Some hope that the disruption can be avoided, and that the agency might remain where it is, with Britain continuing to participate. That seems plausible only if Britain seeks a very close relationship with the European Union, as Norway, Iceland and Liechtenstein did. But those countries agreed to be integrated into the single market, accepting free movement of people as well as goods, capital and services. Prime Minister Theresa May argues that Britons voted against such open borders, and is likely to resist that move.
Outside the bloc, Britain might opt to duplicate the agency’s work, but at a significant cost. Drug companies might require two authorizations for new products — one British, one European — pushing up the prices of medicine.”
This would be on top of the price rises already in the pipeline thanks to the collapse in the pound - still at least we have the £350m a week that was promised - oh hang on.
